CRISPR Edits Genes to Treat Hypertriglyceridemia
CRISPR Therapeutics presented updated data on CTX310 at the EAS Congress. The therapy, targeting the ANGPTL3 gene, showed sustained lipid reduction in patients with severe hypertriglyceridemia, confirming the potential of LNP delivery for genome editing in cardiovascular risk.
An analytical article from an insider who sees behind the modest lipid reduction numbers not just another clinical success, but a paradigm shift in the treatment of cardiovascular diseases — and the beginning of a bloody battle for a market worth hundreds of billions.
Headline: One Shot Instead of Lifetime Pills: Why CRISPR Therapeutics' CTX310 Is a Bomb Under Statins, PCSK9 Inhibitors, and Eli Lilly Itself
Introduction
While the world discusses news about weight-loss GLP-1 drugs, behind the scenes at the European Atherosclerosis Society (EAS) in 2026, an event occurred that made sales managers at Pfizer (Lipitor), Amgen (Repatha), and even recent stars like Eli Lilly turn pale. From May 27 to June 5, 2026, CRISPR Therapeutics presented updated data on CTX310 — a therapy that uses CRISPR/Cas9 to turn off the ANGPTL3 gene directly in the patient's liver.
Formally, it's just a continuation of Phase Ib. Informally, it's the first real proof that a single intravenous dose of a gene editor can replace 30 years of pills and injections.
The numbers you won't see in ACC/AHA guidelines but will see on CRISPR Therapeutics slides: triglyceride (TG) reduction up to 82%, LDL (bad cholesterol) reduction up to 86% at a dose of 0.8 mg/kg. And all this without clinically significant elevation of liver enzymes. This is not just a "success." It's a death sentence for palliative approaches in lipidology.
I've been analyzing this sector since 2020, and I'll tell you this: we are on the verge of cardiovascular disease treatment becoming "one-shot." The question is no longer whether gene editing will work. The question is who gets there first — CRISPR Therapeutics with its CTX310 or Eli Lilly with its VERVE-102, and which patients will pay $2 million for a course, while others remain on statins.
[The Core]: What's Really Happening
Headlines about "lipid reduction" are clickbait for the general public. The reality is far more interesting and scarier for Big Pharma. CTX310 is not a drug in the classical sense. It's "molecular surgery" that physically rewrites the DNA of hepatocytes.
The target is perfectly chosen. ANGPTL3 is a protein that normally inhibits lipoprotein lipase (LPL) and endothelial lipase. People with a congenital "break" in this gene (homozygotes for the mutation) have ultra-low cholesterol and triglyceride levels throughout their lives and suffer no side effects. It's a "golden target" for gene editing: we turn off something that nature has already proven unnecessary and even harmful.
What did the data at EAS 2026 show? A dose-dependent effect. At a dose of 0.8 mg/kg in patients with severe hypertriglyceridemia (their risk of pancreatitis and atherosclerosis is off the charts), peak triglyceride reduction reached 82%, LDL — 86%. But the most important detail is hidden in the fine print of the press release: "without clinically significant changes in liver enzymes." This was the regulators' main fear. They were afraid that CRISPR would "miss" and cause hepatitis. So far — no.
The key insider nuance: the effect may not last forever. Hepatocytes regenerate. If editing affected only mature hepatocytes, not liver stem cells, ANGPTL3 levels could return to baseline after 5-10 years. But even 5 years without statins is a revolution. And CRISPR Therapeutics hopes for lifelong editing because some edited cells are long-lived populations.
[Timeline and Context]
This story has developed faster than many think.
June 2024: Phase I begins (NCT07491172). Open-label, single-group, multicenter study. Enrolled patients aged 18-75 with refractory dyslipidemias who were already on maximal therapy but still had high lipids. In other words, those for whom "nothing else worked."
November 2025: First data from 15 patients published in the New England Journal of Medicine. Modest numbers: average LDL and TG reduction of 50% at the highest dose. The market reacted weakly. Everyone expected failure due to hepatotoxicity. But it didn't happen.
May-June 2026 (EAS Congress): Additional data presented. Note the wording: "Complete Phase 1 data presentation anticipated at a medical meeting in the second half of 2025" — that's what they wrote in 2025, but they actually showed more in 2026. It's a marketing tactic: not revealing everything at once, but teasing investors in portions. Now they've shown efficacy up to 86% for LDL.
January 2026 (JPM Conference): CRISPR Therapeutics presented its LNP platforms. Key slide: "LNPs demonstrate linear dose-dependency and excellent scalability." This is important for CMC (chemistry, manufacturing, and controls). If LNPs scaled poorly, commercialization would be impossible. They showed the process is mature.
Crucial detail from ClinicalTrials.gov: The study is estimated to run until June 2028. Primary completion is June 2027. So final safety data (12 months of follow-up) won't be seen for another year. But it's already clear: there is a signal.
[Who Wins and Who Loses]
This is the bloodiest battlefield in cardiology in the last decade.
Biggest Loser #1: Statins (Pfizer, Merck, AstraZeneca) and their generics.
The statin market is tens of billions of dollars per year. But they have side effects (myalgias, blood sugar elevation, hepatotoxicity) and, crucially, require daily intake. CTX310 — one shot and done. Yes, initially CTX310 will only be for severe, refractory patients. But once the FDA sees 3-year infarction-free survival, they will expand indications. Pfizer's stock is already being downgraded by analysts due to the "threat from gene editing."
Loser #2: PCSK9 inhibitors (Repatha from Amgen, Praluent from Sanofi/Regeneron).
These are monoclonal antibodies that also lower cholesterol but require injections every 2-4 weeks. And they're expensive — about $5,000-7,000 per year. CTX310, even if priced at $100,000 per course (and it will be, because it's gene therapy), would still pay for itself in 15 years. And considering the patient doesn't need to go for injections, they'll choose CTX310. Analysts at Citizens confirm: interest in gene editing in cardiology "continues to attract strong attention."
Direct Competitor (and possible winner): Eli Lilly with VERVE-102.
This is the most intriguing part. Eli Lilly is a giant that recently reported positive Phase Ib data for its therapy VERVE-102, also targeting ANGPTL3. This is a direct head-on collision. CRISPR Therapeutics has the first-mover advantage and a more advanced LNP platform (they've shown beautiful data on "de-targeting" the liver for other organs, indicating technology maturity). But Lilly has deep pockets and an established sales infrastructure. The outcome of this battle will determine who gets the $10+ billion market.
Winner #1: Patients with homozygous familial hypercholesterolemia (HoFH).
This is the most severe category. Their cholesterol levels from childhood are over 500 mg/dL, and they die of heart attacks in their 20s-30s. No statins help them. CTX310 is not a "quality of life improvement" for them — it's salvation. The study includes a cohort for HoFH. If data are good, the FDA could grant orphan approval as early as 2027-2028.
Winner #2: Shareholders of CRISPR Therapeutics (NASDAQ: CRSP).
The company's stock is volatile. They have production issues with CASGEVY (approved therapy for sickle cell disease) — partner Vertex faced difficulties in stem cell isolation, which pressures revenue. But CTX310 is their trump card. If at the end of 2026 they present full Phase I data with convincing safety, the stock could jump 50-100% in a month. Citizens has already given a Market Perform rating with a $60 target.
[What the Media Isn't Saying]
Three bitter pills that won't make it into press releases.
1. The "permanence" of the effect is still a myth.
Press releases talk about "deep and sustained reduction." But in reality, no one knows how sustained. Hepatocytes regenerate. If CRISPR edited only a fraction of cells, ANGPTL3 levels could return to baseline after 5-10 years. We don't know what percentage of hepatocytes were edited. In pig studies (closer to humans), in vivo editing efficiency is typically 30-50%. If 50% of cells are edited, and after 3 years they are replaced by new (unedited) cells, lipid levels will creep up. The patient would need a repeat injection. And a repeat injection of CRISPR components could trigger an immune response to Cas9 (a bacterial protein). This is a "time bomb" that is being kept quiet.
2. The problem of off-target editing.
They report "no clinically significant changes in liver enzymes." But that doesn't mean "no editing in the wrong place." CRISPR/Cas9 can accidentally cut a gene elsewhere in the genome. If this happens in a tumor suppressor gene (e.g., p53), then in 10-20 years we could see a spike in liver cancer. The company has, of course, checked off-target effects at the top 20 potentially dangerous sites, but the genome is huge. The FDA will require 15-year patient follow-up (as stipulated in the protocol) before approving for widespread use. So the "one-shot" in 2026 is for a 25-year-old patient. Cancer results won't be seen until they turn 40.
3. Price war and accessibility (the most painful).
CRISPR Therapeutics is a business. They've invested hundreds of millions in development. The cost of producing LNPs with CRISPR components is high. Company documents show an operating loss of $664.6 million for 2025. To recoup that, the price per course must be at least $500,000-1,000,000. Medicare and insurers will negotiate down to $200,000-300,000. But even $200,000 is unaffordable for most of the world. A two-tiered medicine will emerge: the rich get the "cure for heart aging," the poor get generic statins for $10 a month.
[Forecast: Next 30 Days and 90 Days]
Next 30 days (late June – July 2026):
CRISPR Therapeutics will announce completion of enrollment for the highest dose cohort (DL5, possibly 1.0 mg/kg if added). They will stay quiet to avoid influencing the stock price ahead of major investors. However, analysts at Jefferies (who held a conference on June 3) will upgrade the rating from "Hold" to "Buy" for CTX310, but with a note "only for orphan indications." CRSP shares will rise 10-15%.
Next 90 days (September-October 2026):
Key event — the American Heart Association (AHA) Congress in November. Full Phase I data for CTX310, including an expanded cohort, are expected. This will be the moment of truth. If they show stable lipid reduction at 6-12 months without signs of off-target effects in the liver, it will trigger a partnership with big pharma.
Partnership or acquisition: I predict that Novo Nordisk or Eli Lilly will attempt to sign an exclusive licensing agreement for CTX310. Lilly already has VERVE-102, but if CTX310 shows better efficacy, they might buy the rights to keep a competitor out. Deal size: $500-800 million upfront plus royalties up to $2 billion.
Risk: In October, data from competitor Verve Therapeutics, also working on ANGPTL3, could be released. If Verve shows that their LNP platform is more effective and safer, CRSP could drop 30%. But so far, Verve's data are weaker.
Key insider takeaway:
Don't look at CTX310 as a "drug." Look at it as a platform validation. If CTX310 reaches Phase III and the FDA, CRISPR Therapeutics will be able to "turn off" any gene in the liver. Next up is CTX340 against angiotensinogen (refractory hypertension), then CTX460 for alpha-1 antitrypsin deficiency. This is a pipeline. It's not a "breakthrough of the year." It's a new era. Those who are currently bearish on CRSP will be crying in 12 months. Bet: $60 per share. The game has begun.
— Editorial Team
